NCT06704581: An ongoing trial by BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd.
This trial is ongoing. It must report results 11 months, 2 weeks from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06704581 |
|---|---|
| Title | A Multicenter, Randomized, Double-blind, Placebo-parallel Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of BGM0504 Injection in Chinese Non-diabetes Participants with Overweight or Obese |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Oct. 28, 2024 |
| Completion date | Nov. 27, 2025 |
| Required reporting date | Nov. 27, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |